0001193125-13-289410 Sample Contracts

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT SERVICES AGREEMENT

Services Agreement • July 12th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware

• Contract Type
  Services Agreement
• Filed
  July 12th, 2013
• Company
  Sorrento Therapeutics, Inc.
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  Delaware

This Services Agreement (the “Agreement”) is entered into as of March 7, 2013 (the “Effective Date”) by and between SORRENTO THERAPEUTICS, INC., a Delaware corporation (“STI”) having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“STI”) and IGDRASOL, INC., a Delaware corporation (“IgDraSol”) having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708. STI and IgDraSol may be referred to herein individually as a “Party” and collectively as the “Parties.”

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT OPTION AGREEMENT Dated as of March...

Option Agreement • July 12th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware

• Contract Type
  Option Agreement
• Filed
  July 12th, 2013
• Company
  Sorrento Therapeutics, Inc.
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  Delaware

THIS OPTION AGREEMENT (this “Agreement”) is entered into as of March 7, 2013 by and between IgDraSol, Inc., a Delaware corporation having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708 (“IgDraSol” or the “Company”) and Sorrento Therapeutics, Inc., a Delaware corporation having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“STI” or “Sorrento”).

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT ASSET PURCHASE AGREEMENT

Asset Purchase Agreement • July 12th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  July 12th, 2013
• Company
  Sorrento Therapeutics, Inc.
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  Delaware

THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of March 7, 2013 (“Effective Date”) between IgDraSol, Inc., a Delaware corporation having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708 (“Seller”) and Sorrento Therapeutics, Inc., a Delaware corporation having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“Buyer”).